Tumor angiogenesis: causes, consequences, challenges and opportunities

Roberta Lugano1 · Mohanraj Ramachandran1 · Anna Dimberg1

Received: 12 July 2019 / Revised: 10 October 2019 / Accepted: 21 October 2019 / Published online: 6 November 2019
© The Author(s) 2019

Abstract
Tumor vascularization occurs through several distinct biological processes, which not only vary between tumor type and anatomic location, but also occur simultaneously within the same cancer tissue. These processes are orchestrated by a range of secreted factors and signaling pathways and can involve participation of non-endothelial cells, such as progenitors or cancer stem cells. Anti-angiogenic therapies using either antibodies or tyrosine kinase inhibitors have been approved to treat several types of cancer. However, the benefit of treatment has so far been modest, some patients not responding at all and others acquiring resistance. It is becoming increasingly clear that blocking tumors from accessing the circulation is not an easy task to accomplish. Tumor vessel functionality and gene expression often differ vastly when comparing different cancer subtypes, and vessel phenotype can be markedly heterogeneous within a single tumor. Here, we summarize the current understanding of cellular and molecular mechanisms involved in tumor angiogenesis and discuss challenges and opportunities associated with vascular targeting.

Keywords Angiogenesis · Cancer · Endothelial · Vascular targeting · VEGF · Anti-angiogenic therapy

Introduction
Malignant cells require oxygen and nutrients to survive and proliferate, and therefore need to reside in close proximity to blood vessels to access the blood circulation system. The early observation that rapidly growing tumors were heavily vascularized, while dormant ones were not, led Judah Folkman to propose that initiation of tumor angiogenesis was required for tumor progression [1]. Further, Folkman isolated a tumor-derived factor that induced angiogenesis [2] and hypothesized that inhibition of angiogenic signaling pathways might block new vessel formation and result in tumor dormancy. This exciting concept attracted considerable interest from the research community and spurred extensive efforts dedicated to isolating tumor-derived pro-angiogenic factors and delineating their signaling pathways [3]. In 2003, a clinical trial demonstrating prolonged survival of patients with metastatic colorectal cancer when chemotherapy was administrated in combination with humanized neutralizing antibodies targeting anti-vascular endothelial growth factor (VEGF) resulted in an FDA approval and provided proof-of-concept that anti-angiogenic therapy can be successfully used to treat cancer [4]. Subsequently, several antibodies and tyrosine kinase inhibitors designed to target pro-angiogenic signaling have been approved as cancer therapies. Despite the ever-growing list of FDA-approved drugs, the success of anti-angiogenic therapy has so far been quite limited, only providing short-term relief from tumor growth before resistance occurs and typically resulting in modest survival benefits. The limited efficacy has several explanations including tumors employing alternative modes of angiogenesis and development of resistance mechanisms. In addition, many tumors can obtain access to blood supply through vascular co-option, bypassing the need of tumor angiogenesis [5]. In this review, we summarize the current understanding of molecular and cellular mechanisms involved in tumor angiogenesis, the molecular and functional heterogeneities of tumor vessels and emerging concepts for vascular targeting during cancer therapy.
Initiation of tumor vascularization: the angiogenic switch

Small dormant tumors that are devoid of active blood vessel formation can frequently be observed in human tissue and in genetically engineered mouse models of multistage carcinoma at early stages of cancer progression. Tumor progression is often accompanied by ingrowth of blood vessels, consistent with a need for malignant cells to have access to the circulation system to thrive. Tumors can be vascularized either through co-option of the pre-existing vasculature [5], or by inducing new blood vessel formation through a variety of molecular and cellular mechanisms briefly described below. Vascular homeostasis is regulated by a large number of pro- and anti-angiogenic factors. When these are in balance, the vasculature is quiescent and endothelial cells are non-proliferative. Initiation of blood vessel formation is induced when pro-angiogenic signaling is dominating, a process that in tumors has been coined the “angiogenic switch” [6]. The angiogenic switch releases tumors from dormancy and sparks rapid growth of malignant cells in association with new blood vessel formation. The development of genetically engineered mice modelling multistage tumor progression has been instrumental in investigating the angiogenic switch. One of the most widely studied models is the RIP1-Tag2 model of pancreatic insulinoma expressing the semian virus 40 large T (SV40T) oncogene under the rat insulin promoter, which was developed in Douglas Hanahan’s laboratory [7]. In this model, tumors develop sequentially in mice carrying the transgene, initiating as non-angiogenic clusters of dysplastic cells, of which a proportion later develop to small angiogenic tumor islets that can progress to large vascularized tumors that metastasize to the lung. By combining this and other murine tumor models with advanced in vitro and in vivo models of angiogenesis [8], a wide range of factors and cellular mechanisms have been described that can initiate vessel formation in tumors. The angiogenic switch can be triggered either by additional genetic alterations of tumor cells, leading to increased proliferation and hypoxia or expression of pro-angiogenic factors, or by tumor-associated inflammation and recruitment of immune cells.

Mechanisms of blood vessel formation in tumors

The blood circulation system is critical in delivering nutrients and chemicals to tissues, removing waste products, and maintaining homeostasis. The vascular system, composed of the aorta, arteries, capillaries and veins transports blood throughout the body. Arteries carry blood away from the heart, transporting oxygenated blood to the tissues. The capillary networks have narrow walls that help in gas exchange between the blood and tissues. Oxygen is released into the tissues and carbon dioxide is absorbed by the blood, and is transported back to the heart through veins. Transmigration of immune cells into tissues is facilitated by post-capillary venules. The capillary wall is made of an endothelial cell layer surrounded by a basement membrane and is supported by pericytes. Angiogenesis is typically initiated from the capillaries and it plays an important part in tumor growth, maintenance and metastasis. Blood vessel formation in tumors can be induced through several cellular processes (Fig. 1) as briefly summarized below.

Sprouting angiogenesis

New capillaries can bud from parental vessels through a multi-step process known as sprouting angiogenesis. Formation of sprouts involves (a) Tip cell selection: a cell from the parent vessel becomes the migratory leading cell and blocks its neighboring cells from adopting a tip cell fate by a lateral inhibition process. (b) Sprout extension: the tip cell migrates along the chemotactic path, followed by trailing stalk cells and (c) Lumen formation: connection of the luminal space of the sprout with the parent vessel. The developing sprout then connects with other vessels through a process called anastomosis.

Endothelial cells are normally quiescent, but can be induced to sprout and initiate angiogenesis by pro-angiogenic factors including vascular endothelial growth factor (VEGF). Tip and stalk cell selection is regulated through cross-talk between the VEGF and DII4/Notch pathways [9]. In response to VEGF, tip cells produce Delta-like-4 (DLL4) ligand, platelet derived growth factor-B (PDGF-B), VEGF receptor-2 (VEGFR-2) and VEGFR-3/Flt-4 [10–12]. VEGF blocks Notch signaling and enhance sprouting, branching, migratory capacity and filopodia formation in tip cells [13]. DLL4 secreted by tip cells activated Notch signaling in the neighboring endothelial cells, suppressing tip cell formation by inhibiting VEGFR2 and VEGFR3 expression and inducing VEGFR1 ( decoy for VEGF) expression [14–17]. Tip cells extend numerous filopodia, and acquire motile and invasive phenotypes, secreting matrix degrading proteins that guide new blood vessel formation towards the VEGF gradient [18]. Neurophilins, which are non-tyrosine kinase receptors, promote tip cell function by enhancing signaling through VEGFR2 and VEGFR3 [19, 20]. Stalk cells follow the tip cells and branch out from the parent vessel, establishing the vascular lumen and junctional connections to the forming sprout.
They are more proliferative and have fewer filopodia as compared to the tip cells, a process fine-tuned by Notch-regulated ankyrin repeat protein [21]. The term vascular anastomosis defines development of junction between two new sprouts (‘head-to-head’ anastomosis) or a sprout and an existing blood vessel (‘head-to-side’ anastomosis). Live imaging studies in Zebrafish indicate that development of cell junctions is a highly stereotypical process [22–24]. Migrating tip cell filopodia express junctional proteins such as VE-cadherin [25, 26]. The filopodia from adjacent tip cells make and break contacts many times during initial contact formation, after which VE-cadherin is deposited at a single point of filopodia contact and a ring shaped junction is formed to create a small luminal pocket at this site [22, 25, 27]. Next, the excess filopodia retract, membranes of the anastomosing fuse, express apical markers like podocalyxin, and upregulate expression of junctional molecules on the cell surface [25]. The different mechanisms by which the lumen and perfused tubes form are termed type I and type II anastomosis, reviewed in detail by Betz et al. [28].

**Intussusceptive angiogenesis**

A less studied process of neo-angiogenesis is “intussusception”, where transluminal tissue pillars develop within existing vessels and subsequently fuse to remodel the vascular plexus, first described in remodeling of lung capillaries [29, 30]. The molecular mechanisms involved in intussusceptive angiogenesis are not completely understood, but the process can be induced by growth factors including VEGF, PDGF and erythropoietin [31–33]. Intussusceptive angiogenesis have been observed in various tumor types including melanoma, colorectal cancer, glioma and mammary tumors [34–37]. In melanoma, VEGF expression correlates with the occurrence of intussusceptive angiogenesis and the number of intraluminal tissue folds [34]. Xenografts of human adenocarcinoma utilize intussusceptive angiogenesis as a mode
for rapid vascular remodeling and maintenance of blood flow in tumors [36]. Intussusceptive angiogenesis is thought to contribute to tumor growth by increasing the complexity and number of microvascular structures within the tumor.

**Vasculogenesis and recruitment of endothelial progenitor cells**

De novo blood vessel formation in the embryo is induced through differentiation and association of endothelial progenitor cells (EPCs) in a process coined vasculogenesis [38, 39]. In mice, progenitor cells differentiate and assemble into clusters called blood islands, as early as embryonic day (E) 6.5–7 [40]. A subset of cells located at the perimeter of the blood islands, termed angioblasts give rise to precursors for endothelial cells, while those at the center differentiate to hematopoietic cells. Angioblasts migrate to the paraxial mesoderm, assemble into aggregates, proliferate and differentiate to form a plexus with endocardial tubes in mouse. This leads to formation of dorsal aortae, cardinal veins and the embryonic stems of arteries and veins in the yolk sac. Vasculogenesis is also described in adults during capillary formation post ischemia [41] or in tumors as alternative mechanism for neo-vascularization to meet the increasing need for oxygen and nutrient supply [42]. In preclinical glioma models, it has been shown that revascularization that occurs during glioma recurrence after irradiation is mediated by vasculogenesis and not angiogenesis [43]. Vasculogenesis in tumors is mediated by recruitment of EPCs or bone marrow–derived hematopoietic cells, resulting in the formation of new vessels to support tumor growth [44, 45]. EPCs are mostly unipotent adult stem cells that have the capacity to self-renew, proliferate, take part in neovascularization and repair endothelial tissue [46, 47]. They were first identified in 1997 by Asahara et al. [41]. EPCs are characterized by expression of CD34, VEGFR1, CD133, Tie-2 (endothelial receptor tyrosine kinase), Nanog and Oct-4 (Octamer-4), and by their ability to bind Ulex-lectin and uptake acetylated low-density lipoproteins [48, 49]. EPCs can be derived from hematopoietic stem cells, myeloid cells, circulating mature endothelial cells or other circulating progenitor cells [46, 50]. EPCs contribute to postnatal vasculogenesis, and are recruited from the bone marrow to sites of injury via growth factors, cytokines and hypoxia-related signaling pathways, where they differentiate into mature endothelial cells and incorporate themselves into sites of active neovascularization [41, 51]. In tumors, vasculogenesis is initiated by crosstalk between tumor cells and EPCs in the bone marrow. VEGF in the tumor microenvironment mobilizes VEGFR2+ EPCs from the bone marrow [52–54]. Tumors also secrete other factors well known to mobilize EPCs to the tumor bed and promote neovascularization, including chemokines C–C motif ligand (CCL)2 and CCL5, the hypoxia responsive chemokine CXCL12 (also known as SDF-1) [55] and adiponectin [55–57].

**Vascular mimicry**

Aggressively growing tumor cells can form vessel like structures through a process denoted as vascular mimicry. These structures, which are formed without contribution of endothelial cells, represent an alternate channel for tumor cells to source sufficient blood supply and nutrients. Vascular mimicry has been observed in many tumor types including melanoma [58], glioma [59], head and neck cancer [60], lung cancer [61], colorectal cancer [62] and prostate cancer [63]. The existence and relative importance of vascular mimicry was initially debated and questioned in the field [64], but has since been supported by findings of several research groups [65]. Structures formed through vascular mimicry are identified in tumor samples with IHC using CD31 and periodic acid–Schiff (PAS) as markers [66]. The endothelial-like tumor cells can secrete collagens IV and VI, proteoglycans, heparan sulfate, laminin and tissue transglutaminase antigen 2, aiding in tubular structure formation and stabilization [67]. Tumor cells participating in vascular mimicry in uveal melanoma have a multipotent, stem cell-like phenotype and express CD271 [68]. Both vascular mimicry and fibrovascular septa are present in the stroma of melanoma and can be distinguished by their thickness and lamination [69].

Vascular mimicry can contribute to tumor progression in several ways. In melanoma, mitochondrial reactive oxygen species induce activation of the Met proto-oncogene under hypoxic conditions, promoting vascular mimicry. This results in tumor cell motility, invasion, and metastasis [70]. In gliomas, increased vascular mimicry has been reported following anti angiogenic therapy [71]. This may serve as an alternative neovascularization process adopted by the tumor to cope with the therapy and counteract the hypoxic environment. Vascular mimicry is a marker for poor prognosis in several cancer types [62, 72]. However, there is a lack of techniques that can be used to clearly distinguish vascular mimicry from normal endothelial cell lining, which hampers investigations of the relative importance of this process.

**Trans-differentiation of cancer stem cells**

Trans-differentiation of cancer stem cells to endothelial cells and vascular smooth muscle-like cells, giving rise to neovascularization, has been reported in several tumor types [59, 73–76]. Tumor endothelial cells have in some studies been observed to harbor similar somatic mutations as the malignant cells of the tumor, indicating a neoplastic origin [59, 73]. Trans-differentiation of glioma cells to endothelial cells in vitro was demonstrated by culturing of glioma
cancer stem cells in endothelial-promoting media, resulting in expression of pan-endothelial markers CD31, CD34 and vWF, formation of tubular structures and uptake of LDL [59, 77]. In vivo xenografts of human glioma stem cells were observed to develop tumor vessels with endothelial cells expressing human endothelial proteins CD34, CD144, and VEGFR2. Selective therapeutic targeting of tumor-derived cells expressing Tie-2 could disrupt the vasculature and eradicate the tumor, leading the authors to conclude that glioma stem cell derived endothelial cells contributed to vascularization of glioma [59]. However, these results have been controversial and the clinical relevance has been questioned since endothelial cells in human glioblastoma have not been observed to harbor genetic alterations in other studies [78, 79]. Notably, Tie-2 is not only a marker of endothelial cells, but is also expressed by proangiogenic monocytes and pericytes [80]. A later study using lineage-specific fluorescent reporters did not support tumor cells as a source of endothelial cells in glioma, instead demonstrating that glioma cancer stem cells can differentiate into pericytes and that specific depletion of pericytes disrupted tumor vessels and tumor growth [81]. The trans-differentiation of glioma cancer stem cells to pericytes was enhanced by TGFβ, and their recruitment to endothelial cells was mediated by CXCL12/CXCR4 signaling [81].

### Molecular and functional features of tumor blood vessels

While physiological blood vessels formation occurring during development, menstrual cycle or wound healing is a tightly controlled process that ceases when the need for new blood vessels have been met, tumor angiogenesis is deregulated due to a persistence of pro-angiogenic factors in the tumor microenvironment. Efficient circulation depends on an ordered division of the vascular tree into arteries, arterioles, capillaries, venules and veins. However, in the presence of constant pro-angiogenic signaling in the tumor, the newly formed vascular networks may fail to mature and prune, the division into arterioles, capillaries and venules may be lacking, vessel caliber size can be markedly heterogeneous and blood flow through the poorly organized and malformed vessels can be chaotic [82, 83]. This can lead to uneven blood flow within the tumor parenchyma resulting in areas of persisting or intermittent hypoxia [84, 85]. Endothelial junctions are often disrupted in tumor vessels, leading to enhanced permeability, and interstitial fluid pressure is increased [86]. This can in turn reduce the efficacy of cancer therapy since compression of tumor vessels and poor vascular perfusion hamper drug delivery [87]. Pericytes are generally partially detached from endothelial cells in tumor vessels, and the basement membrane is unevenly distributed, leading to increased vessel fragility and risks of hemorrhage [88–90]. Defects in vascular function and integrity profoundly alters the tumor microenvironment (Fig. 2a–c). However, the extent of structural and functional abnormalities observed in tumor vessels vary greatly depending on the tumor type and anatomical location, and also within the same tumor depending on the tumor microenvironment.

Aside from the structural and functional defects observed within the tumor vasculature, tumor blood vessels are molecularly distinct from normal vessels since they respond to environmental cues by transcriptional regulation of gene expression [91–99]. Transcriptional signatures of tumor endothelial cells may vary depending on the anatomic location, the tumor type and the malignancy grade. However, tumor vessels typically up-regulate subsets of genes that are transcriptionally active also during developmental and physiological angiogenesis. Consistent with this, a meta-analysis of transcriptional profiles from different types of human cancer identified a core gene signature including, e.g. VEGFR2, TIE1 and TIE2 which are central regulators of pro-angiogenic VEGF and angiopoietin signaling [100]. This tumor angiogenesis core gene signature also included CLEC14A and CD93, which together with endosialin and thrombomodulin constitute a C-type lectin family that are frequently up-regulated in tumor vessels [95, 101–106]. CLEC14A, CD93 and endosialin all bind to the secreted extracellular matrix associated protein multimerin-2 [107, 108]. The interaction between endothelial CD93 and MMRN2 regulates fibronectin deposition during glioma angiogenesis, and loss of endosialin, mainly expressed in pericytes, protects against development of fibrosis, suggesting that this protein family participates in regulating the extracellular matrix [105, 109]. However, CD93-deficiency is associated with increased permeability, while endosialin expression in pericytes promotes intravasation of tumor cells and metastatic dissemination, indicating opposite roles in regulating vascular integrity [104, 110]. The specific transcriptional response of tumor endothelial cells is not only related to angiogenesis and vessel integrity, but may also affect endothelial activation and recruitment of leukocytes. Pro-angiogenic signaling leads to endothelial anergy, reduced response to pro-inflammatory signaling and decreased regulation of adhesion molecules and chemokines necessary for capture and trans-endothelial migration of leukocytes [111–114]. Up-regulation of FASL in tumor vessels further strengthens the endothelial barrier and contributes to immune suppression by inducing apoptosis of cytotoxic T-lymphocytes [115]. Similarly, expression of endotherlin B in tumor vessels in ovarian cancer has been shown to decrease T cell homing [116]. Especially in brain tumors, the changes in endothelial gene expression induced by the tumor microenvironment can also be beneficial for therapy. The specific gene expression signature induced in tumor endothelial cells in WNT-medulloblastoma leads to
disruption of the blood brain barrier and thereby renders the tumor sensitive to chemotherapy [117]. Proteins that are up-regulated in tumor vessels alter vascular function, and may constitute new targets for therapy as discussed further below.

**Growth factor and chemokine signaling in tumor angiogenesis**

A large number of pro-angiogenic factors and their cognate receptors are known to promote vessel formation in tumors, including vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet derived growth factor (PDGF), angiopoietins, ephrins, apelin (APLN) and chemokines. These factors are often expressed simultaneously, effectively co-operating at different stages of tumor angiogenesis. The main functions and features of the most prominent pro-angiogenic factors are discussed briefly below.

**Vascular endothelial growth factors (VEGF)**

The vascular endothelial growth factor family consists of five secreted proteins, VEGF (also referred to as VEGF-A),
VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF).

VEGF, originally identified as vascular permeability factor (VPF), is one of the most potent inducers of angiogenesis [118]. In cancer, VEGF is produced and secreted by tumor cells and surrounding stroma and is associated with tumor progression, increased vessel density, invasiveness, metastasis and tumor recurrence [119].

VEGF is up-regulated during hypoxia and orchestrates blood vessel formation mainly via activation of VEGF receptor-2 (VEGFR-2) expressed by endothelial cells [120]. VEGFR-2 activation initiates several signaling pathways leading to specific endothelial responses such as cell survival, proliferation, migration, invasion, vascular permeability and vascular inflammation [121]. A tight coordination of these cellular processes is crucial for a successful establishment of new vessels. During tumor angiogenesis, VEGF secreted by tumor cells induces endothelial cell proliferation and survival primarily via the ERK and PI3K/Akt pathways [122, 123]. Endothelial cell migration downstream of VEGFR2 is induced via multiple signaling pathways, often involving PI3K stimulation and activation of Rho GTPases [124]. On the other hand, VEGF-mediated cell invasion is promoted by the expression of MT (membrane type)-MMP (matrix metalloproteinase), MMP-2, MMP-9 and urokinase plasminogen activator which degrade the basal membrane and extracellular matrix allowing migration of endothelial cells and the formation of capillary sprouts [123, 125].

Vascular permeability is crucial for normal tissue homeostasis and is considered a prerequisite for VEGF-induced angiogenesis. VEGF induces vascular permeability by several mechanisms, including junctional remodeling, induction of fenestrae, and vesiculo-vascular organelles (VVOs) [126]. In pathological conditions such as cancer, dysregulation of these mechanisms leads to vascular hyper-permeability that in turn may exert direct effects on the tumor microenvironment including increased interstitial pressure and impaired therapeutic delivery [127]. Moreover, the leaky vasculature may facilitate the escape of tumor cells into the bloodstream promoting the establishment of distant metastases [128].

Vascular permeability is tightly related to vascular inflammation. Although VEGF is not an inflammatory cytokine, VEGF can induce the activation of the transcription factor NFAT in endothelial cells via PLCγ/calcineurin, promoting an inflammatory gene expression pattern similar to that of IL-1β [129]. In addition, VEGF-mediated activation of NF-κB downstream of Akt can induce an inflammatory-type response, promoting the attraction of leukocytes that can contribute to the angiogenic process. [123].

PIGF is a member of the VEGF family; however, its role in modulating tumor angiogenesis has been a subject of controversy. PIGF has been reported to enhance pathological angiogenesis by initiating a cross-talk between VEGFR-1 and VEGFR-2 [130], while others have demonstrated anti-angiogenic properties of PlGF [131]. Similarly, there have been contradictory results regarding the efficiency of anti-PIGF therapy in inhibiting angiogenesis and halting tumor growth in preclinical tumor models [132, 133].

**Fibroblast growth factor-2 (FGF2)**

The mammalian fibroblast growth factor (FGF) family comprises 22 molecules, 18 of which interact with high affinity to tyrosine kinase receptors FGFR1, FGFR2, FGFR3 and FGFR4 [134]. FGFs are secreted glycoproteins that are sequestered in the extracellular matrix. To signal, FGFs are released from the extracellular matrix by heparinases, proteases or specific FGF binding proteins, and the liberated FGFs subsequently bind to cell surface heparan sulphate proteoglycans (HSPGs) stabilizing the FGF-FGFR interaction [135].

FGFs that signal through FGFR regulate a broad spectrum of biological functions and can involve both tumor cells and the surrounding stroma. These effects include cellular proliferation, resistance to cell death, increased motility and invasiveness, enhanced metastasis as well as increased angiogenesis [134]. FGF-2, also known as basic FGF (bFGF), is the most characterized pro-angiogenic mediator in physiological conditions as well as during tumor progression [136, 137]. FGF-2 exerts its effects on endothelial cells via a paracrine signaling after being released by tumor and stromal cells or mobilized from extracellular matrix. It has been described that FGF-2 can promote angiogenesis acting together with VEGF, by inducing the secretion of MMPs, plasminogen activator and collagenase responsible for the degradation and organization of the extracellular matrix [134]. In addition, a recent study has identified FGF signaling as a key regulator of blood and lymphatic vascular development by modulating endothelial metabolism driven by MYC-dependent glycolysis, which is crucial for endothelial cell sprouting, migration and proliferation [138]. In tumors, FGF expression has been associated with resistance to anti-angiogenic therapy. Indeed, activation of the proangiogenic FGF signaling pathway has been proposed to be a mechanism that the tumor cells use to escape from VEGF-targeted therapies. A recent study performed in a murine breast cancer model shows that FGF receptor inhibition leads to decreased vessel density and restored tumor sensitivity to anti-VEGF therapy [139].

**The platelet derived growth factor (PDGF) family**

The PDGF family comprise four heparin-binding polypeptide growth factors denoted A, B, C, and D. PDGF is secreted by activated platelets, endothelial, epithelial, glial cells as well as inflammatory cells and it targets a broad spectrum of cell type including, fibroblasts, pericytes,
smooth muscle cells, glial cells or mesangial cells [140]. PDGF signals through two cell-surface tyrosine kinase receptors, PDGFRα and PDGFRβ, and regulates many biological functions including angiogenesis, by promoting vessel maturation and recruitment of pericytes and by inducing upregulation of VEGF [141]. All members of the PDGF family display potent angiogenic activity in vivo, however, the PDGF-B/PDGFRβ axis is the most characterized. The importance of PDGF in vessel function was demonstrated by lethality of mice lacking components of the PDGF-B/PDGFRβ pathway, displaying vessel leakage and micro-hemorrhage [142].

PDGF and PDGFR are involved in cancer development and progression through autocrine stimulation of tumor cell growth and paracrine stimulation on stromal cells inducing tumor-associated angiogenesis. In an experimental model of glioma, PDGF-B enhanced angiogenesis by stimulating VEGF expression in tumor-associated endothelial cells and by recruiting pericytes in newly-formed vessels [143].

**Angiopoietins**

Angiopoietins (ANGPTs) are growth factors that regulate development, maintenance and remodeling of the blood vessels, and they play a key role in controlling tumor growth and angiogenesis. The human angiopoietin family comprises the ligands ANGPT-1, ANGPT-2, and ANGPT-4 [144, 145]. Angiopoietins signaling is mediated by endothelial receptor tyrosine kinases TIE-1 and TIE-2, TIE-2 being the best characterized [146].

ANGPT-1 and ANGPT-2 both bind to TIE-2, but elicit very different responses. ANGPT-1 promotes vessel maturation and stabilization of the newly-formed vessels through the Akt/survivin pathway. In contrast, ANGPT-2 has been shown to induce vessel destabilization, pericyte detachment, vessel sprouting and angiogenesis [147]. Increased ANGPT-2 expression has been observed in activated endothelial cells during inflammation and in tumor-associated vessels of several human cancers in response to hypoxia and VEGF [148]. Moreover, ANGPT-2 has been identified as an autocrine regulator of endothelial cell inflammatory response by sensitizing endothelial cells towards TNF and inducing upregulation of adhesion molecules [149].

Upregulation of ANGPT-2 in glioblastoma has been associated with reduced efficacy of anti-VEGF treatment and increased therapy resistance [150]. Preclinical studies have demonstrated beneficial effects on inhibiting tumor progression by dual inhibition of ANGPT-2/VEGFR2. Indeed, simultaneous ANGPT-2 and VEGFR2 inhibition impairs tumor growth, prolong vessel normalization and blocks macrophage recruitment improving survival of glioma bearing mice [151, 152]. Co-targeting of ANGPT-2/VEGFR2 is also effective in other murine tumor models, including early breast cancer, colorectal and renal cancer [153].

**Eph/ephrin signalling**

The Eph proteins belong to the superfamily of receptor tyrosine kinases and include 14 human type 1 transmembrane protein members. The Eph proteins are divided in two subgroups, EphA and EphB based on their sequence homologies and the ability to bind their ligands, the ephrins. The EphA subgroup includes nine members (EphA1-A8 and A10) and the EphB subgroup five members (EphB1-B4, B6). Unlike other tyrosine kinases whose ligands are soluble proteins, the Ephs ligands are associated with the plasma membrane of expressing cells and are classified in two subclasses based on the type of membrane binding. The ephrins A include six members (A1–A6) and are attached to the membrane by a glycosylphosphatidylinositol (GPI) domain. The Ephrins B are single pass type 1 transmembrane proteins and this subclass includes three members (B1–B3) [154].

A unique features of Eph receptors and their membrane anchored ligands is their ability to mediate bi-directional signals (forward and reverse signal) between adjacent cells. The “forward signal” occur when Eph/ephrin signal transduce into receptor-binding cell and the “reverse signal” when the ligand-receptor interaction leads to transduction into the ligand-expressing cell, reviewed in [155].

Ephrins and Eph receptors are involved in several processes that occur during embryogenesis including vascular development, tissue-border formation, cell migration and axon guidance [156, 157]. However, an important role Eph/ephrins system has also been found in pathological conditions such as cancer [158, 159]. Many ephrins and Eph receptors are upregulated in human tumors such as breast, colon, liver, brain, prostate and melanoma and are often associated with tumor progression and metastasis [158, 159]. On the other hand, also downregulation of Eph receptors can lead to increased metastasis as shown for EphA1 in colorectal cancer, EphA7 in prostate carcinomas, and EphB6 in melanoma [160, 161].

Several studies directly associate Eph/ephrins system to tumor angiogenesis. Ogawa et al. [162] was one of the first to report tumor vasculature-specific expression of EphA2 and ephrinA1 in blood vessels of preclinical models of breast carcinoma and Kaposi’s sarcoma. Subsequently, it was found that blocking EphA receptor signalling using soluble EphA receptors decreases tumor vascular density, tumor volume and cell proliferation [163–165].

EphB4-ephrinB2 signalling was also associated with increased tumor angiogenesis and tumor progression [166] as well as with resistance to anti-angiogenic therapy [167]. Indeed, in this preclinical study of glioma, EphB4
overexpression was associated with alterations in vascular morphogenesis, pericyte coverage, cellular proliferation and apoptosis, inducing a vascular phenotype resistant to therapy. Furthermore, a recent study identified EphrinB2 as a regulator of perivascular invasion and proliferation of glioblastoma stem-like cells [168]. Importantly, a connection between ephrins and VEGF signalling has also been shown. In particular, it was found that ephrin-B2 is able to control VEGF signalling by inducing VEGFR2 and VEGFR3 internalization, thereby regulating angiogenesis and lymphangiogenesis in physiological conditions as well as during tumor progression [169, 170].

**Apelin/APLNR pathway**

Apelin (APLN) is an endogenous peptide-ligand of the G protein-coupled receptor APJ (APLR) [171]. The APLN/APLNR signaling pathway is involved in developmental angiogenesis, where the APLNR expression is predominantly restricted to the ECs of the developing vascular system and APLN regulates vascular patterning in the embryo [172–174]. APLN/APLNR signaling has key function in several physiological processes like cardiac function, angiogenesis, metabolism and body fluid homeostasis, and also in pathological conditions like heart failure, cancer, obesity and diabetes (reviewed in detail [175]).

The APLN/APLNR pathway is upregulated in malignant cells in many tumor types [174, 176, 177], as well as in tumor endothelial cells [178], and elevated Apelin levels are associated with disease progression and poor clinical outcome [176, 179–181]. Apelin expression in tumors is regulated by hypoxia [181] and is suggested to promote tumor growth in several ways. Apelin directly stimulates tumor cell proliferation [181–183], tumor cell migration and metastasis [184, 185]. Apelin also stimulates neoangiogenesis and microvascular proliferation within the tumor, leading to enhanced tumor growth [174, 176, 186, 187].

The clinical outcome of targeting APLN/APLNR pathway for cancer therapy depends on the tumor type. In models of lung and breast cancer, targeting Apelin prevented resistance associated with anti-angiogenic therapy by reducing tumor growth, metastasis and improving vessel function [188]. In models of glioma, targeting Apelin promoted invasiveness of tumor cells positive for APLNR. However, combined targeting of VEGFR2 and Apelin improved survival of glioma bearing mice [189]. In another glioma study targeting APLNR with a competitive antagonist reduced tumor growth in mice [190]. In a renal cell carcinoma study, APLNR expression in a subset of patients was found to be negatively correlated with tumor PD-L1 expression [177]. This also indicates a role of APLN/APLNR signaling in the regulation of immunological processes, which needs to be further investigated.

**Chemokines**

Chemokines are a large family of small secreted proteins with conserved cysteine residues that act through binding G-protein linked chemokine receptors with seven transmembrane structures. Depending on the number of amino acids separating the cysteine residues that make up the disulfide bonds that are required for structural integrity, chemokines are classified into CC, CXC, XC and CX3C subclasses [191]. The CXC chemokines are further divided into ELR + or ELR− groups depending on the presence or absence of a Glu-Leu-Arg motif preceding the first cysteine residue in the N-terminus, which is essential to regulate chemotaxis across endothelium. Chemokines mediate specific homing of progenitor cells and leukocytes expressing their cognate receptors. In cancer, chemokines contribute to tumor angiogenesis either directly through binding chemokine receptors expressed on endothelial cells, or indirectly through recruitment of inflammatory cells and progenitors.

ELR + CXC chemokines, including CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 enhance angiogenesis through binding to their common receptor CXCR2. CXCR2 can be expressed in microvascular endothelial cells [192], and in tumor vessels in several types of human cancer [193, 194]. Inhibition of CXCR2 decreased tumor growth and angiogenesis in a genetic murine model of pancreatic ductal adenocarcinoma [195]. In human ovarian carcinoma cells, CXCR2 activation induced angiogenesis through enhanced expression of VEGF and knockdown reduced tumorigenesis in nude mice [196]. Expression of ELR + chemokines may also induce angiogenesis indirectly, since CXCR2 can be expressed on neutrophils and is involved in leukocyte arrest prior to transendothelial migration [197]. Among the CXC ELR + chemokines, especially CXCL8 has been found to be important for tumor angiogenesis in several tumor types [198, 199]. It can support endothelial survival and induce release of pro-angiogenic factors such as VEGF, MMP-2 and MMP-9 [200–203]. CXCL8 is a strong neutrophil attractant, and induces neutrophil respiratory burst upon recruitment [204].

CXCL12/SDF1 binds to CXCR4 and is the only CXC ELR- chemokine that is directly pro-angiogenic and chemotactic, while other chemokines in this group, including CXCL4, CXCL9 CXCL10, CXCL11 and CXCL14 have angiostatic effects [205]. CXCR4 is enriched in tip cells and highly expressed in tumor vessels [11, 206]. Hypoxia-induced stabilization of HIF1α leads to up-regulation of CXCL12, which in turn mediates recruitment of CXCR4-expressing endothelial progenitor cells from the bone marrow, thereby contributing to vasculogenesis [207]. In addition, CXCL12/CXCR4 is involved in vessel co-option and trafficking of leukocytes to the tumor.
CCL2 is expressed in tumors and affects endothelial permeability and metastasis through interacting with CCR2 expressed on tumor endothelial cells [208]. Endothelial progenitor cells expressing CCR2 can be recruited from the circulation in response to tumor expression of CCL2, contributing to tumor angiogenesis [209]. The necessity of CCL2 for mobilization of endothelial progenitor cells was demonstrated in a genetic murine breast cancer model, exhibiting reduced numbers of these cells in the blood in Her2/neu CCL2-deficient mice [209]. Survival of Her2/neu mice was increased by treatment with CCXC872, a small molecule antagonist targeting CCR2.

Other proangiogenic factors contribute to tumor angiogenesis

During tumor progression, expression of various matrix metalloproteases (MMPs) either by the tumor cells or by surrounding stromal cells, helps to remodel the ECM and release ECM- and membrane-bound growth factors promoting tumor progression, metastasis and tumor-associated angiogenesis. Transcription of MMPs can be induced by various signals including cytokines, growth factors, and mechanical stress. Secretion of MMP-2 and MMP-9 activate the latent form of transforming growth factor-beta (TGF-β), further promoting tumor invasion and angiogenesis [210]. TGF-β is an important regulator of neovascularization in tumor and it acts in a context-dependent manner by promoting angiogenesis via stimulation of pro-angiogenic factors like VEGF or inhibiting tumor angiogenesis by impairing endothelial cell proliferation and migration or by inducing apoptosis [211].

Tissue necrosis factor-α (TNF-α) is an inflammatory cytokine released by macrophages, mast cells and T-lymphocytes and it is also implicated in tumor progression, cell survival, differentiation, invasion, metastases as well as secretion of cytokines and pro-angiogenic factors. The effect of TNF on angiogenesis, however, is controversial. Indeed, it has been reported that depending on its temporal expression during the angiogenic process it can exert pro- or anti-angiogenic effects by regulating the expression of VEGFR2 [212].

Another pro-angiogenic factor expressed in tumors is pleiotrophin (PTN), a small heparin-binding cytokine that is abundant in the brain during embryonic development and is re-induced during pathological conditions [213]. PTN level is increased in several types of cancer including glioma, breast cancer, lung cancer, melanoma, neuroblastoma, pancreatic cancer, and prostate cancer, and may increase tumor growth either through direct effects on tumor cells or through stimulation of angiogenesis and remodeling of the tumor microenvironment [214, 215].

High levels of PTN correlates with poor survival of patients with astrocytomas and is associated with vascular abnormalities. Studies in murine glioma models have provided evidence that PTN can enhance tumor growth through stimulation of the tumor vasculature [216].

Many other factors potentially regulating angiogenesis in tumors have been identified, but have not yet been fully explored. Neurite outgrowth inhibitor or Nogo belongs to the reticulon 4 (RTN4) protein families, which consists of three major splicing isoforms (NogoA, Nogo-B, and Nogo-C) with distinct expression patterns that binds to NgR receptors [217, 218]. An essential role of Nogo-B in regulating vascular remodeling was reported in Nogo-A/B-deficient mice [219]. Mice that are deficient for Nogo-A/B exhibit reduced arteriogenesis and angiogenesis in vivo due to impaired macrophage infiltration [219, 220]. More recently it has been reported that the expression level of Nogo-B is upregulated in hepatocellular carcinoma and Nogo-B deficiency suppressed the tumor growth and metastasis [221]. The expression level of Nogo-B correlated with tumor vessel density in hepatocellular carcinoma and anti-Nogo-B antibody inhibited tumor growth in vivo via suppressing tumor angiogenesis [222].

Hypoxia or genetic alterations leading to stabilization of HIF induce tumor angiogenesis

Hyper-proliferation of tumor cells results in increased oxygen consumption, and when the tumor mass surpass the blood supply the tumor becomes hypoxic. Hypoxia induces production of pro-angiogenic factors leading to enhanced, rapid and chaotic blood vessel formation. Cellular adaptation to hypoxia is primarily mediated by a family of transcriptional regulators, hypoxia-inducible factors (HIFs). HIFs are heterodimers consisting of an oxygen-dependent α-subunit (HIF-α) and an oxygen-independent β-subunit (HIF-β). HIF-α has three isoforms, HIF-1α, HIF-2α, and HIF-3α. HIF-1α being the major responsible for activating transcriptional responses under hypoxia [223]. Hypoxia-induced stabilization of HIF-1α promote the upregulation of several pro-angiogenic genes including VEGF, FGF and PDGF [224].

Genetic alterations in the oxygen-signaling pathway can influence the activation of HIF under normoxic condition. The von Hippel-Lindau (VHL) protein plays a central role in the oxygen-sensing pathway promoting HIFα proteosome-mediated degradation during normoxia. Mutations in this gene, resulting in the stabilization of HIF-1α and activation of the target pro-angiogenic genes is found in many tumors and it is associated with tumor progression and poor patient outcome [225].
Contributions of immune cells to tumor angiogenesis

The tumor microenvironment is comprised of a broad array of stromal cells, endothelial cells, immune and inflammatory cells. The malignant cells and cells within the tumor microenvironment continuously interact with each other to develop a dynamic and tumor-promoting milieu [226]. Notably, there is tight and mutual interplay between the immune and endothelial cells. Immune cells depend on the expression of adhesion molecules on endothelial cells for extravasation into tumor tissue, where they can exhibit their anti-tumor properties. On the other hand, immune cells are a source for several soluble factors that influence angiogenesis, endothelial cell behavior and subsequent tumor progression. The impact of different immune subsets on angiogenesis and endothelial cell remodeling is well studied [227–229]. The contribution of the most prominent immune cell types (macrophages, myeloid derived suppressor cells, neutrophils and lymphocytes) to tumor angiogenesis and endothelial cell remodeling are discussed below.

Macrophages

Macrophages are specialized phagocytes that clear invading microbes and cell debris, present antigens to the adaptive immune system and release various immunomodulatory cytokines. They are very plastic cells, able to exist in a range of different phenotypes based on stimuli in the tissue microenvironment [230]. The two extremes of this range are the pro-inflammatory M1 phenotype, associated with active microbial killing, and the M2 phenotype, associated with immune suppression, tissue remodeling and angiogenesis [231]. Tumor-associated macrophages (TAMs) can have different phenotypes depending on the tumor microenvironment, but generally closely resemble M2 macrophages [232].

TAMs are known to modulate and support angiogenesis. Depletion of TAMs results in the inhibition of tumor angiogenesis, whereas reconstitution of TAMs promotes angiogenesis in murine cancer models [233, 234]. Hypoxia in the tumor microenvironment simulates metabolic adaptation of TAMs and pro-angiogenic characteristics. Primarily, TAMs promote angiogenesis by producing multiple proangiogenic factors facilitating the proliferation of endothelial cells, induction of sprouting, tube formation, and maturation of new blood vessels. These factors include VEGFA, VEGFC, VEGFD, EGF, FGF2, chemokines (CXCL8, CXCL12, TNFα and MCP-1), semaphorin 4D, adrenomedullin, and thymidine phosphorylase [231, 235–237, 237]. TAMs release a number of angiogenesis-modulating molecules that include enzymes (COX-2, iNOS) [238], matrix metalloproteinases (MMPs-1, 2, 3, 9, and 12) [239], cathepsin proteases [240] and plasmin, urokinase plasminogen activator [241]. They act in synergy and trigger degradation of the basement membrane and extracellular matrix components, destabilizing the vasculature and promoting migration and proliferation of endothelial cells. TAMs can also promote angiogenesis by inhibiting the expression of angiogenesis inhibitors, such as vasohibin-2 [242]. TAMs expressing Tie2 (TEMs) have been identified to be closely associated with the blood vessel and transmit angiogenic signals at least partially by the expression of FGF-2 [80]. TEMs support vessel stability by antagonizing the effect of vascular disrupting agents and promoting tumor growth [243].

Myeloid-derived suppressor cells (MDSCs)

MDSCs are a heterogeneous population of immature myeloid cells that expand and accumulate under pathological conditions such as infection, trauma, autoimmune diseases and cancer. MDSCs are broadly classified in two sub-populations, the monocytic MDSC (M-MDSC) and granulocytic MDSC (G-MDSC), which exist both in humans and mice [244] [245]. However, there are no clear set of markers to differentiate G-MDSCs and neutrophils, and there has therefore been a debate and confusion in the field concerning the identity and relationship between these two cell types [246]. MDSC recruitment to the tumor can be induced by many different factors e.g. CSF3, IL-1β, and IL-6, and subsequently lead to activation of STAT3, rendering them potent as proangiogenic and immunosuppressive cells [247].

The capability MDSC regulating tumor angiogenesis is similar to M2-like TAMs. MDSCs promote and sustain tumor angiogenesis primarily by secretion of MMPs. In particular, MMP-9 is known to boost angiogenesis and stimulate tumor neovascularization by increasing the bioavailability of VEGF [248]. This initiates a feedforward loop as VEGF can further trigger MDSC recruitment [249]. MDSC accumulation in the tumor correlates with intra-tumoral VEGF concentration during disease progression [250]. In the presence of VEGF, MDSCs can create a pro-angiogenic milieu within the tumors by secreting angiogenic factors including CCL2, CXCL8, CXCL2, IL-1β, ANGPT1, ANGPT2, and GM-CSF [251, 252]. These chemokines can further promote MDSCs accumulation in the tumor creating a vicious circle. They also express Bv8, also known as prokineticin 2, which plays an important role in MDSC mediated angiogenesis [253]. Accumulation of MDSCs in the tumor microenvironment induces resistance to anti-angiogenic therapy [254, 255], while MDSC ablation has synergistic effects with anti-VEGF/VEGFR treatment [249, 256].
Neutrophils

Neutrophils are the most abundant leukocyte population, providing the first line of defense against invading pathogens. They are a rich source of soluble factors such as ROS, peptides, cytokines and enzymes that exert antimicrobial activities [257]. Neutrophils are one of the main sources of VEGF and are known to play an important role during physiological angiogenesis, for example in endometrial angiogenesis during the menstrual cycle [258, 259]. Other studies have demonstrated that depletion of neutrophils affects neo-vascularization in animal models of angiogenesis [260, 261].

Conclusive evidence of neutrophils involvement in tumor angiogenesis came from studies in the RIP1-Tag2 multi-step pancreatic carcinogenesis mouse model. Neutrophil depletion using anti-GR1 antibodies reduced the number of dysplastic islets that were undergoing angiogenesis [262]. In addition, two subtypes of neutrophils have been reported at least in murine tumor models: TGFβ-independent type 1 (N1) with antimicrobial functions, and TGFβ-dependent, tumor-associated neutrophils (N2, TANs) possessing pro-tumor and pro-angiogenic functions [263, 264]. Neutrophil survival and proliferation in tumors depend on CSF3-CSF3R mediated activation of STAT3 signaling. STAT3 activation in neutrophils triggers the angiogenic switch through secretion of VEGF, IL-8, TNF-α, MMP9, FGF2, ANGPT-1 and HGF in mice [265–267]. CSF3 is also known to stimulate neutrophils to secrete Bv8 and induce myeloid cell mobilization in tumors and promote myeloid-dependent angiogenesis [253]. MMP9-producing TANs contribute to the initiation of angiogenic switch and acceleration of tumorigenesis [262]. TANs usually lack expression of tissue inhibitors of metalloproteinases (TIMP1), rendering them more angiogenic than cells that are capable of producing TIMP1/MMP9 complexes [268].

Lymphocytes

There are three major types of lymphocytes, namely T cells and B cells, which constitute the adaptive immune system and NK cells, which are part of the innate immune system. The contribution of lymphocytes towards tumor angiogenesis is not as well understood, as that of myeloid cell types.

A subset of NK cells (CD56brightCD16− KIR+, dNK cells), characterized by poor cytotoxicity and pro-angiogenic capacity have been identified in the decidua during pregnancy. They secrete VEGF, placental growth factor (PIGF), IFNγ, IL-10 and CXCL8 that are critical for spiral artery formation and decidual vascularization [269, 270]. TGFβ promotes dNK cell polarization and can induce VEGF and PIGF secretion from healthy donor NK cells [271, 272]. In the presence of TGFβ, NK cells convert to type 1 innate lymphoid cells, leading to evasion of immune response and an inability to control tumor growth and metastasis [273].

The ability of B cells to modulate tumor angiogenesis depends on activation of STAT3. Transfer of B cells expressing STAT3 to Rag1−/− mice leads to enhanced tumor growth accompanied with increased angiogenesis. This is a result of an interaction between STAT3-activated B cells and endothelial cells through production of VEGF [274]. B cells also contribute to tumor angiogenesis via antibody-mediated activation of Fcγ receptors on TAMs, inducing secretion of IL-1. This leads to recruitment of myofibroblasts and promotion of tumor angiogenesis [275].

T cells promote angiogenesis by secretion of pro-angiogenic factors FGF-2 and heparin-binding epidermal-like growth factor (HB-EGF) [276]. However, the most prominent T cell derived factors, such as TNF, TGFβ, and interferons (IFNs), have anti-angiogenic functions [277–279]. The antiangiogenic effects of IFNs are mediated by direct effects on endothelial cells and other cells in the tumor microenvironment. Treatment with IFN-α/β induced necrosis of endothelial cells within tumors and decreased tumor metastases to the liver and spleen [280]. In vitro, TNF and IFNs can block collagen synthesis and extracellular matrix formation and thus inhibit the formation of capillary-like structures [281, 282]. IFN-γ can inhibit neovascularization and induce apoptosis if endothelial cells in murine glioma models [277]. Type-1 polarized T cells (Th1) secrete IFNγ and their presence in the tumor microenvironment usually correlates with good clinical outcome [283]. Interferon-induced CXC family chemokines inhibit endothelial cell proliferation, promote Th1 type T cell, NK and DC infiltration, thereby inhibiting tumor growth. CXCL9, CXCL10 and CXCL11 are interferon-inducible angiostatic chemokines that can directly inhibit angiogenesis by binding CXCR3 on endothelial cells [284–286].

Anti-angiogenic therapy: successes and failures

The concept of targeting angiogenesis as a means to starve tumors was introduced by Judah Folkman and colleagues 48 years ago [1]. Since then, several antiangiogenic therapies, mainly targeting VEGF signaling pathway have been developed and approved for the treatment of a variety of tumors (Table 1). Despite promising results showed by preclinical studies, anti-VEGF monotherapy such as bevacizumab, sunitinib and aflibercept among others have only provided limited benefits in certain tumor types including advanced-stage renal cell carcinoma, hepatocellular carcinoma and colorectal carcinoma and have not shown efficacy in pancreatic adenocarcinoma, prostate cancer, breast cancer or melanoma [287]. Data obtained by the AVANT trial of
adjuvant bevacizumab in colorectal cancer shows evidence of higher incidence of relapses and deaths in bevacizumab treated patients due to disease progression suggesting an increased tumor aggressiveness after anti-angiogenic therapy [288]. This is consistent with studies in experimental models of cancer, which correlate anti-angiogenic treatment

| Drug                      | Target molecule(s)                                                                 | Tumor type                                                                                                                                                                                                 | References |
|---------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Monoclonal antibodies     |                                                                                    |                                                                                                               |            |
| Bevacizumab               | VEGF-A                                                                             | Colorectal cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, renal cell carcinoma, glioblastoma                             | [4, 335–339] |
| Ramucirumab               | VEGFR-2                                                                            | Gastric or gastro-oesophageal junction cancers, colorectal cancer, hepatocellular carcinoma, non-small-cell lung carcinoma                        | [340–343]  |
| Cetuximab                 | EGFR                                                                               | Squamous cell carcinoma of the head and neck, colorectal cancer                                               | [344, 345]  |
| Panitumumab               | EGFR                                                                               | Colorectal cancer                                                                                              | [346]      |
| Necitumumab               | EGFR                                                                               | Squamous non-small-cell lung cancer                                                                            | [347]      |
| Trastuzumab               | HER2                                                                               | HER2-positive breast cancer, HER2-positive advanced gastric or gastro-oesophageal junction cancer              | [348, 349] |
| Pertuzumab                | HER2                                                                               | HER2-positive breast cancer                                                                                                         | [350]      |
| Tyrosine kinase inhibitors|                                                                                    |                                                                                                               |            |
| Sorafenib                 | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR family, RAF                                       | Hepatocellular carcinoma, renal cell carcinoma, thyroid cancer                                                | [351–353]  |
| Sunitinib                 | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR family, Kit, FLT3, CSF-1R, RET                   | Gastrointestinal stroma tumor, pancreatic cancer, renal cell carcinoma                                        | [354–356]  |
| Imatinib                  | PDGFR, c-Kit, Abl                                                                   | Gastrointestinal stroma tumor, myeloid leukemia, philadelphia chromosome-positive acute lymphoblastic leukemia | [357–359]  |
| Pazopanib                 | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR family, Kit, Itk, LcK, c-FMS                      | Renal cell carcinoma, soft tissue sarcoma                                                                   | [360, 361] |
| Gefitinib                 | EGFR                                                                               | Non-small cell lung cancer                                                                                      | [362]      |
| Erlotinib                 | EGFR                                                                               | Non-small cell lung cancer, pancreatic adenocarcinoma                                                         | [363, 364] |
| Vandetanib                | VEGFR-2, FGFR family, RET, BRT, Tie-2,EPH, Src family                             | Medullary thyroid cancer                                                                                      | [365]      |
| Regorafenib               | VEGFR-2, VEGFR-3, PDGFR-β, RAF, RET, Kit                                          | Colorectal cancer, Gastrointestinal stroma tumor, hepatocellular carcinoma                                  | [366–368]  |
| Neratinib                 | EGFR, HER-2                                                                        | HER-2 positive breast cancer                                                                                   | [369]      |
| Lapatinib                 | EGFR, HER-2                                                                        | HER-2 positive breast cancer                                                                                   | [370]      |
| Afatinib                  | EGFR, HER-2                                                                        | Non-small cell lung cancer                                                                                     | [371]      |
| Axitinib                  | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR family, Kit                                      | Renal cell carcinoma                                                                                          | [372]      |
| Cabozantinib              | VEGFR-2, c-Met                                                                     | Hepatocellular carcinoma, medullary thyroid cancer, renal cell carcinoma                             | [373–375] |
| Lenvatinib                | VEGFR-1, VEGFR-2, VEGFR-3, FGFRs, PDGFR-α, KIT, RET                               | Hepatocellular carcinoma, thyroid cancer                                                                    | [376, 377] |
| Receptor fusion proteins  |                                                                                    |                                                                                                               |            |
| Ziv-aflibercept (VEGF trap)| VEGF-A, VEGF-B, PI GF                                                              | Colorectal cancer                                                                                             | [378]      |
| Immunomodulatory agents with anti-angiogenic effect |                                                                                   |                                                                                                               |            |
| Thalidomide               | TNF-α, ILs, IFNs, VEGF, bFGF                                                       | Multiple myeloma                                                                                              | [379]      |
| Lenalidomide              | TNF-α, ILs, IFNs, VEGF, bFGF                                                       | Multiple myeloma                                                                                              | [380]      |
| mTOR inhibitor with anti-angiogenic effect |                                                                                   |                                                                                                               |            |
| Everolimus                | mTOR                                                                               | Renal cell carcinoma, breast cancer, pancreatic cancer, gastrointestinal cancer, lung neuroendocrine tumor, subependymal giant cell astrocytoma | [381–385] |
with increased local tumor invasiveness and formation of distant metastasis [289–292]. In glioma, numerous clinical studies collectively show that anti-angiogenic treatment can prolong progression-free survival but fails to improve overall survival [293]. The limited success of anti-angiogenic therapy in glioma is likely at least in part due to an escape from therapy by invasive tumor cells co-opting the vasculature of the surrounding brain tissue. Several molecular mechanisms have been identified that may explain resistance and increased invasion after anti-angiogenic therapy in glioma, including mesenchymal transition of tumor cells, up-regulation of pro-angiogenic factors, activation of MET and up-regulation of MMPs [293–296]. Metastasis-promoting effects have mainly been obtained from experimental models and clear evidence from clinical studies is still lacking. The reasons underlying insufficient efficacy of vessel-targeting strategies have been extensively investigated, and include stroma and tumor cell mechanisms of resistance [287, 297].

**Mechanisms of resistance to anti-angiogenic therapy**

Resistance to anti-angiogenic therapy is an important issue that likely explains the variable response in different types of tumors and the limited overall survival benefits. Resistance can be classified into intrinsic resistance, observed from the outset of the therapy, and acquired resistance, observed after an initial positive response to therapy [297]. Several mechanisms have been proposed for anti-angiogenic therapy resistance, including direct effects of hypoxia such as induction of tumor invasion and metastasis, co-option of normal vessels in the surrounding tissue, vascular mimicry as well as the contribution of stromal cells including recruitment of TAMs, EPC and pro-angiogenic myeloid cells as well as the upregulation of alternative pro-angiogenic factors [297] [298].

As already mentioned, anti-angiogenic therapy can promote tumor invasion and metastasis in pre-clinical cancer models, which might be triggered by increased hypoxia due to vessel depletion. Indeed, the transcription of HIF-regulated genes controls different steps of tumor invasion and metastasis, including EMT, activation of MET signaling, recruitment of stromal cells, vascular mimicry and vessel co-option [299]. Vessel co-option is defined as a non-angiogenic process whereby tumor cells directly utilize the pre-existing vasculature of the non-malignant tissue as a supply of oxygen and nutrients, resulting in resistance to anti-angiogenic therapy [5]. The first evidence of vessel co-option as a mechanism of acquired resistance to anti-angiogenic therapy was demonstrated by a study in a mouse model of hepatocellular carcinoma investigating the response to sorafenib treatment [300]. In addition to vessel co-option, tumor cells can develop vascular mimicry as an alternative blood transportation system to counteract the lack of oxygen and nutrient upon anti-angiogenic therapy. Indeed, preclinical studies conducted in renal carcinoma model reported that the VEGFR2 inhibitor sunitinib increases vascular mimicry under hypoxia by transforming tumor cells into endothelial-like cells resulting in tumor resistance [301].

Recruitment of stromal cells, immune cells and progenitors is another potential mechanism for resistance to anti-angiogenic therapy. In particular, many studies have pointed out an important role of bone marrow derived cells (BMDCs) in this aspect. Recruitment of BMDCs in glioblastoma can cause resistance to vatalanib treatment and the depletion of BMDCs can potentiate the effects of this anti-angiogenic drug [302]. Release of proangiogenic factors and increased hypoxia in response to vasculization blockade can lead to recruitment of endothelial progenitor cells (EPC) from the bone marrow, which contribute to tumor vascularization and have been linked to development of resistance to anti-VEGF therapy [303]. Moreover, recruitment of proangiogenic myeloid cells is also considered to be a mechanism whereby tumors bypass the inhibitory effects of antiangiogenics drugs. Tumors can recruit different populations of myeloid cells with pro-angiogenic properties which in turn can be used as an alternative source of pro-angiogenic chemokines and cytokines [304].

In addition, alternative pro-angiogenic signaling pathways including ANGPT-2, FGF-2, IL-8 can be induced by tumor cells in response to a pharmacological inhibition of the VEGF signaling pathway [297]. In recent years, progress has been made towards understanding the mechanism of action of anti-angiogenic drugs through evaluating the effects of anti-angiogenic inhibitors on tumor vessels in pre-clinical and clinical studies. An important aspect that have emerged is the broad spectrum of effects covered by the angiogenic inhibitors and the diversity in terms of therapeutic response [305].

**Mechanisms mediating the therapeutic effect of angiogenesis inhibitors**

Although anti-angiogenic drugs were initially designed to block blood vessel formation, their ability to control tumor growth may be due to several different mechanism, which are not mutually exclusive. To improve vascular targeting, a thorough understanding of the cellular and molecular mechanisms that hinder tumor progression in response to anti-angiogenic therapy in specific tumors is necessary. The possible mechanism of actions of angiogenesis inhibitors on tumor blood vessels can be broadly classified into three categories: (a) vessel depletion, (b) vessel normalization, and (c) immune activation (Fig. 3).
Fig. 3 Effects of anti-angiogenic therapy. The mechanism of actions of angiogenesis inhibitors on tumor blood vessels can be classified into three categories: a vessel depletion, b vessel normalization, and c immune activation. a Vessel depletion result in tumor cell starvation and an increased tissue hypoxia. Enhanced hypoxia may promote the recruitment of pro-angiogenic myeloid cells and the mobilization of tumor cell from the hypoxic tissue to the normal tissue as well as co-option of normal vessels. In addition, the depletion of tumor vessels results in an inefficient delivery of anti-cancer drugs. b Normalization of tumor blood vessels achieved by restored endothelial cell junctions, increased pericyte coverage and re-established blood flow result in decrease tissue hypoxia and increased drugs delivery. In addition, vessel normalization promote the expression of endothelial adhesion molecule facilitating immune cell infiltration. c Immune activation, induced by anti-angiogenic drugs include dendritic cell (DC) maturation, activation and infiltration of T-cell as well as the polarization of tumor associated macrophages (TAM) towards an M1-like phenotype. In addition, a decrease in regulatory T-cells (Treg), myeloid derived suppressor cells (MDSCs) and mast cells have been observed in response to anti-angiogenic therapy
Vessel depletion

The development of anti-angiogenic drugs was initiated by the hypothesis that starving tumors by blocking angiogenesis would slow tumor progression and improve patient survival [1]. Early preclinical studies were promising and demonstrated a significant tumor growth delay and reduced metastasis. However, the effects of anti-angiogenic agents administrated as monotherapy in cancer patients during clinical trials often failed to show significant survival benefits. These observations suggest that anti-angiogenic therapy alone is insufficient to induce substantial tumor shrinkage in most cancer patients. Particular attention must be placed on the effects of tumor vessel depletion on the tumor microenvironment as well as the development of anti-angiogenic resistance. Indeed, as mentioned above, hypoxia induced by vessel depletion can activate several mechanisms used by tumor cells to counteract the lack of oxygen and nutrients such as increased tumor invasiveness and co-option of normal vessels resulting in ineffective anti-angiogenic therapy.

Several studies demonstrate that before reaching complete depletion of the vascular bed, anti-VEGF drugs induce an early and transient phase in which vessels assume normal shape and function [306, 307]. This vessel normalization window is characterized by a rescue of the balance between pro- and anti-angiogenic factors and it can promote increase tumor drug delivery and efficacy.

Vessel normalization

Despite a high vascular density, tumors are usually hypoxic and nutrient-deprived since the tumor vessels are abnormal, leaky and malfunction. Such abnormal vasculature significantly compromises the efficacy of most anti-cancer therapies by limiting the delivery of drugs as well as promoting resistance to treatment.

The vessel normalization hypothesis, introduced by Rakesh Jain in 2001 [308] suggests that rather than depleting vessels, a sub-maximal doses of anti-angiogenic therapy can restore the normal function and structure of tumor vessels and improve drug delivery. This hypothesis could explain the increased progression-free survival observed in patients treated with anti-angiogenic drugs combined with chemotherapy as compared to treatment with chemotherapy alone [309]. Evidence supporting the idea that vessel normalization can improve cancer therapy has been obtained in mouse models. These studies show that improving tumor vessel perfusion and oxygenation ameliorates the efficacy of conventional therapies such as radiotherapy, chemotherapy and immunotherapy and reduces metastatic dissemination [309, 310].

Evidence that support the notion that vessel normalization occur in response to anti-angiogenic therapy has also been obtained from clinical studies. The functionality of the tumor vasculature in glioblastoma patients treated with anti-VEGF therapies has been evaluated by magnetic resonance imaging (MRI). MRI analysis of patients treated with cediranib revealed a decrease in vessel diameter, vascular permeability, and edema. More importantly, survival of patients with recurrent glioblastoma following cediranib-treatment was found to correlate with a vascular normalization index [311]. Improved perfusion occurred only in a subset of glioblastoma patients treated with cediranib, and was associated with improved patient overall survival [312]. These observations suggest that the degree of vessel normalization in terms of improved perfusion may be used as a tool to distinguish responders to anti-angiogenic therapy from non-responding patients [312, 313].

Immune activation

Pro-angiogenic factors in tumors induce down-regulation of adhesion molecules on endothelial cells in the tumor vasculature and induce anergy to inflammatory signals such as TNFα and IL-1. Hereby, tumors with an angiogenic phenotype may escape the infiltration of cytotoxic leukocytes [111]. Using anti-angiogenic agents can potentially overcome the down-regulation of adhesion molecules and the unresponsiveness to inflammatory signals [314]. Consistent with this, normalization of tumor vasculature through anti-VEGF therapy in combination with adoptive T-cell transfer was found to increase tumor T-cell infiltration and improve survival in murine melanoma model [314].

Inhibition of VEGF signaling in the tumor microenvironment may be beneficial not only in terms of improving immune cell recruitment, but can also directly improve immune cell activation. Normalization of the tumor vascular network and decreased hypoxia can promote T cell infiltration and induce polarization of TAM to an M1-like phenotype [315]. Anti-angiogenic therapy can also reduce the prevalence of immunosuppressive cells. Decreases in Treg recruitment as well as MDSC has been reported after sunitinib treatment in tumor-bearing mice and in patients with metastatic renal carcinoma [316, 317]. In addition, inhibition of angiogenic signaling may improve T-cell priming and activation by improving dendritic cell (DC) maturation. Anti-angiogenic therapy using the VEGF-neutralizing antibody bevacizumab was found to increase the number and the maturation of DCs in patients with metastatic non-small cell lung carcinoma [318]. These observations indicate that immune activation is an additional mechanism that can contribute to response to anti-angiogenic therapy.

Concluding remarks—arising opportunities for vascular targeting in cancer

Tumor vessels are often dysfunctional and anergic to inflammatory stimuli, leading to a hostile tumor microenvironment that fuel cancer progression and aggravate
therapeutic approaches. Current vascular targeting strategies are based on inhibition of key angiogenic signaling pathways known to promote tumor angiogenesis. Although several anti-angiogenic drugs have been approved, intrinsic and acquired resistance to therapy limit their efficacy. An increased understanding of tumor vessel phenotype and mechanisms involved in treatment response and resistance to therapy is necessary to overcome the hurdles that prevent successful control of the angiogenic response in tumors. Alternatively, vascular targeting should instead be designed to target the tumor vessels in new ways that are conceptually different from inhibition of angiogenesis. This may involve altering the timing and dosing of already existing anti-angiogenic therapy in combination with other drugs, or development of novel therapeutics to either directly target the tumor vessels or optimize their function to fit the cancer therapy at hand.

**Differential gene expression in tumor vessels provides new tools for vascular targeting**

The fact that tumor vessels differ molecularly from their normal counterparts can be used to develop treatment strategies that specifically target malignant cells and tumor vasculature. Therapeutic vaccination strategies to raise endogenous antibodies against antigens specifically expressed by tumor vasculature have shown efficacy in pre-clinical cancer models [319]. Prophylactic immunization of the alternatively spliced extra domain (ED)-B of fibronectin efficiently reduced growth of syngeneic subcutaneous tumors [320], and therapeutic vaccination against ED-A after tumor development reduced metastatic dissemination in the MMTV-PyMT model of metastatic mammary carcinoma [321]. Antibodies targeting tumor vessel markers have also been used. Blocking the tumor endothelial marker TEM8/anthrax toxin receptor 1 using antibodies raised against the extracellular domain inhibited angiogenesis, decreased growth of human tumor xenografts and increased the effect of anticancer drugs [322]. Conjugating TEM8-targeting antibodies with cytotoxic monomethyl auristatin E was successful in specifically directing the drug to the tumor microenvironment of orthotopic tumors and patient derived xenografts, significantly inducing regression or eradication of tumor growth in pre-clinical models [323]. Using an alternative strategy, targeting tumor endothelium and TEM8-positive malignant cells by employing TEM8-specific CAR T cells was effective in treating triple negative breast cancer (TNBC) patient derived xenograft (PDX) models and metastatic TNBC cell-line xenografts [324]. Peptides that specifically bind tumor endothelial cells have also been used to target either therapeutic antibodies or chemokines to the tumor microenvironment to improve efficacy and decrease toxicity [325, 326].

**Tailoring tumor vessels to optimize cancer therapy**

Going beyond anti-angiogenesis and vascular normalization, strategies that can alter vessel phenotype to optimize specific types of cancer therapy are quickly emerging. It is already established that targeting VEGF/VEGFR signaling can enhance the efficacy of cancer immunotherapy by increasing expression of adhesion molecules and chemokines necessary for capture and transendothelial migration of T-cells [327, 328]. Several clinical trials have been initiated aimed at improving immunotherapy by combining checkpoint inhibitors with vascular targeting (http://clinicaltrials.gov) [327, 328]. To provide an even more efficient gateway for T-cells to enter the tumor microenvironment, tumor vessels can be induced to differentiate to high-endothelial venules (HEVs). HEVs have a distinct morphology, built up by cuboidal endothelial cells, and they express chemokine and adhesion molecules that mediate efficient recruitment of lymphocytes into the tissue [329]. Depletion of Tregs in a model of fibrosarcoma led to HEV neogenesis, enabling recruitment of T-cells into the tumor [330]. The presence of HEV within the tumor was a pre-requisite for tumor control after Treg depletion. Subsequently, it was found that activated CD8+ T cells induced HEV development within the tumor after Treg depletion [331]. Consistent with a role of activated T-cells in HEV neogenesis, combining anti-angiogenic therapy with anti-PD-L1 immunotherapy was sufficient to induce HEVs in several orthotopic and genetically engineered mouse models of cancer, stimulating tumor immunity [332]. Specific targeting of LIGHT/TNFSF14 to tumor vessels using vascular targeting peptides improved vessel functionality, activated endothelial cells and induced formation of HEV in murine glioblastoma, associated with enhanced accumulation of lymphocytes [333]. With respect to brain tumors, strategies that transiently open the blood brain barrier to enable delivery of drugs are of considerable interest [334]. The observation that paracrine signaling in WNT-medulloblastoma was associated with fenestrated tumor vessels that lack ABC transporters suggests that brain tumor vessels can indeed be modulated to allow a better penetration of drugs [117]. This exciting possibility has yet to be explored therapeutically. It is necessary to gain a deeper understanding of how tumor vessel function is altered in specific cancer types, and how vessel phenotype can be modulated. This may lead to new vascular targeting strategies aimed at tailoring vessel function to optimize drug response.

**Acknowledgements** Open access funding provided by Uppsala University, Swedish Cancer Society (CAN 2017/502), the Swedish Childhood Cancer Society (PR2018-0148), the Swedish Research Council (Dnr
2016-02495), Emil and Wera Cornells Stiftelse foundation. AD was supported by a Senior Investigator Award from the Swedish Cancer Society. Mohanraj Ramachandran was supported by a postdoc position from the Swedish Childhood Cancer Society.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186
2. Folkman J et al (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133(2):275–288
3. Cao Y et al (2011) Forty-year journey of angiogenesis translation research. Sci Transl Med 3(114):114rv3
4. Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
5. Kuczynski EA et al (2019) Vessel co-option in cancer. Nat Rev Clin Oncol 16(8):469–493
6. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353–364
7. Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncoproteins. Nature 315(6015):115–122
8. Nowak-Sliwinska P et al (2018) Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 21(3):425–532
9. Jakobsson L, Bentley K, Gerhardt H (2009) VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 37(Pt6):1233–1236
10. Tammela T et al (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454(7204):656–660
11. Strasser GA, Kaminker JS, Tessier-Lavigne M (2010) Microarray analysis of retinal endothelial tip cells identifies CXCR11 as a mediator of tip cell morphology and branching. Blood 115(24):5102–5110
12. Shawber CJ et al (2007) Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest 117(11):3369–3382
13. Jakobsson L et al (2010) Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 12(10):943–953
14. Hellstrom M et al (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445(7129):776–780
15. Lobov IB et al (2007) Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA 104(9):3219–3224
16. Harrington LS et al (2008) Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res 75(2):144–154
17. Funahashi Y et al (2010) Notch regulates the angiogenic response via induction of VEGFR-1. J Angiogenes Res 2(1):3
18. Gerhardt H et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161(6):1163–1177
19. Fantin A et al (2013) NRPI acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. Blood 121(12):2352–2362
20. Segarra M et al (2012) Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood 120(19):4104–4115
21. Hellstrom M et al (2007) Dll4 signalling through Notch1 for the tip cell position during angiogenic sprouting. Nat Cell Biol 11(8):1942–1948
22. Herwig L et al (2011) Distinct cellular mechanisms of blood vessel fusion in the zebrafish embryo. Curr Biol 21(22):1942–1948
23. Kochhan E et al (2013) Blood flow changes coincide with cellular rearrangements during blood vessel pruning in zebrafish embryos. PLoS One 8(10):e75060
24. Lenard A et al (2015) Endothelial cell self-fusion during vascular pruning. PLoS Biol 13(4):e1002126
25. Lenard A et al (2013) In vivo analysis reveals a highly stereotypic morphogenetic pathway of vascular anastomosis. Dev Cell 25(5):492–506
26. Hellstrom M, Stanchi F, Gerhardt H (2013) Filopodia are dispensable for endothelial tip cell guidance. Development 140(19):4031–4040
27. Blum Y et al (2008) Complex cell rearrangements during intersegmental vessel sprouting and vessel fusion in the zebrafish embryo. Dev Biol 316(2):312–322
28. Betz C et al (2016) Cell behaviors and dynamics during angiogenesis. Development 143(13):2249–2260
29. Patan S et al (1992) Intussusive microvascular growth: a common alternative to capillary sprouting. Arch Histol Cytol 55(Suppl):65–75
30. Burri PH, Tarek MR (1990) A novel mechanism of capillary growth in the rat pulmonary microcirculation. Anat Rec 228(1):35–45
31. Hestrom M et al (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14):3047–3055
32. Wilting J et al (1996) VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of choioallantoic membrane. Dev Biol 176(1):76–85
33. Crivellato E et al (2004) Reombinant human erythropoietin induces intussusive microvascular growth in vivo. Leukemia 18(2):331–336
34. Ribatti D et al (2005) Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusive microvascular growth in primary melanoma. Oncol Rep 14(1):81–84
35. Nico B et al (2010) Intussusive microvascular growth in human glioma. Clin Exp Med 10(2):93–98
36. Patan S, Munn LL, Jain RK (1996) Intussusive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 51(2):260–272
37. Djovon V et al (2001) MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours. J Pathol 195(2):147–155
38. Risau W et al (1988) Vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusive microvascular growth in primary melanoma. Dev Biol 125(2):35–45
39. Choi K (1998) Hemangioblast development and regulation. Biochem Cell Biol 76(6):947–956

Springer
41. Ashara T et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302):964–967
42. Bussolati B, Grange C, Camussi G (2011) Tumor exploits alternative strategies to achieve vascularization. FASEB J 25(9):2874–2882
43. Kiot M et al (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120(3):694–705
44. Ahn JB et al (2010) Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett 288(1):124–132
45. Greenfield JP, Cobb WS, Lyden D (2010) Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas. J Clin Invest 120(3):663–667
46. Chopra H et al (2018) Insights into endothelial progenitor cells: origin, classification, potentials, and prospects. Stem Cells Int 2018:9847015
47. Schmidt A, Brixius K, Bloch W (2007) Endothelial precursor cell migration during vasculogenesis. Circ Res 101(2):125–136
48. Romagnani P et al (2005) CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 97(4):314–322
49. Shin JW et al (2005) Isolation of endothelial progenitor cells from cord blood and induction of differentiation by ex vivo expansion. Yonsei Med J 46(2):260–267
50. Urbich C, Dimmelser S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95(4):343–353
51. Reale A et al (2016) Functional and biological role of endothelial precursor cells in tumour progression: a new potential therapeutic target in haematological malignancies. Stem Cells Int 2016:7954580
52. Ashara T et al (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18(14):3964–3972
53. Hattori K et al (2001) Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193(9):1005–1014
54. Kopp HG, Ramos CA, Rafii S (2006) Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 13(3):175–181
55. Chang EI et al (2007) Hypoxia, hormones, and endothelial progenitor cells in hemangioma. Lymphat Res Biol 5(4):237–243
56. Spring H et al (2005) Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 102(50):18111–18116
57. Nakamura N et al (2009) Adiponectin promotes migration activities of endothelial progenitor cells via Cdc42/Rac1. FEBS Lett 583(15):2457–2463
58. Maniotis AJ et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155(3):739–752
59. Ricci-Vitiani L et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325):824–828
60. UpleT et al (2011) Vascular mimicry in cultured head and neck tumour cell lines. Head Neck Oncol 3:55
61. Williamson SC et al (2016) Vasculogenic mimicry in small cell lung cancer. Nat Commun 7:13322
62. Baeten CI et al (2009) Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 52(12):2028–2035
63. Sharma N et al (2002) Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 50(3):189–201
64. Fausto N (2000) Vasculogenic mimicry in tumors. Fact or artifact? Am J Pathol 156(2):359
65. Seftor RE et al (2012) Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 181(4):1115–1125
66. Folberg R, Maniotis AJ (2004) Vasculogenic mimicry. APJMS 112(7–8):508–525
67. Angara K, Borin TF, Arbab AS (2017) Vascular mimicry: a novel neovascularization mechanism driving anti-angiogenic therapy (AAT) resistance in glioblastoma. Transl Oncol 10(4):650–660
68. Valyi-Nagy K et al (2012) Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in threedimensional cultures. Mol Vis 18:588–592
69. Lin AY et al (2005) Distinguishing fibrovascular septa from vasculogenic mimicry patterns. Arch Pathol Lab Med 129(7):884–892
70. Comito G et al (2011) HIF-1alpha stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51(4):893–904
71. Angara K et al (2017) Vasculogenic mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies. Histol Histopathol 32(9):917–928
72. Li M et al (2010) Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 16(2):259–266
73. Wang R et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833
74. Mei X et al (2017) Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging. Neuro Oncol 19(8):1109–1118
75. Bussolati B et al (2009) Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med 13(2):309–319
76. Alvero AB et al (2009) Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 27(10):2405–2413
77. Zhao Y et al (2010) Endothelial cell transdifferentiation of human glialoma stem progenitor cells in vitro. Brain Res Bull 82(5–6):308–312
78. Kulka A et al (2003) Analysis of the TP53 gene in laser-microdissected glioblastoma vasculature. Acta Neuropathol 105(4):328–332
79. Rodriguez FJ et al (2012) Neoplastic cells are a rare component of human glioma microvasculature. Oncotarget 3(1):98–106
80. De Palma M et al (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211–226
81. Cheng L et al (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153(1):139–152
82. Baluk P, Hashimzade H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15(1):102–111
83. McDonald DM, Baluk P (2005) Imaging of angiogenesis in inflamed airways and tumors: newly formed blood vessels are not alike and may be wildly abnormal: Parker B. Francis lecture. Chest 128(6 Suppl):602S–608S
84. Kimura H et al (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56(23):5522–5528
85. Bennethwaite KL, Durand RE (2004) Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 64(17):6183–6189
86. Hashimzade H et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4):1363–1380
87. Padera TP et al (2004) Pathology: cancer cells compress intratumour vessels. Nature 427(6976):695
88. Abramsson A et al (2002) Analysis of mural cell recruitment to tumor vessels. Circulation 105(1):112–117
89. Morikawa S et al (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160(3):985–1000
90. Baluk P et al (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163(5):1801–1815
91. St Croix B et al (2000) Genes expressed in human tumor endothelium. Science 289(5482):1197–1202
92. Zhang L et al (2003) Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63(12):3403–3412
93. Carson-Walter EB et al (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61(18):6649–6655
94. Huang X et al (2010) Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 207(3):505–520
95. Dieterich LC et al (2012) Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFbeta2 in vascular normalization. J Pathol 228(3):378–390
96. Roudnicky F et al (2013) Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 73(3):1097–1106
97. Zhao Q et al (2018) Single-cell transcriptome analyses reveal endothelial cell heterogeneity in tumors and changes following antiangiogenic treatment. Cancer Res 78(9):2370–2382
98. Buckanovich RJ et al (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25(7):852–861
99. Zhang L et al (2018) IDH mutation status is associated with disease: beyond discovery and development. Cell 176(6):1248–1264
100. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581–611
101. Claesson-Welsh L, Welsh M (2013) VEGFA and tumor angiogenesis. J Intern Med 273(2):114–127
102. Takahashi T et al (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20(11):2768–2778
103. Jiang BH, Liu LZ (2009) PI3 K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19–65
104. Lamalice L, Le Boeuf F, Huot J (2007) Endothelial cell migration during angiogenesis. Circ Res 100(6):782–794
105. van Hinsbergh VW, Koolwijk P (2008) Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78(2):203–212
106. Wei SM, Cheshier DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437(7058):497–504
107. Azzii S, Hebdia JK, Gavard J (2013) Vascular permeability and drug delivery in cancers. Front Oncol 3:211
108. Wei S et al (2004) Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167(2):223–229
109. Hofer E, Schweighofer B (2007) Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 97(3):355–363
110. Autiero M et al (2003) Role of PI(3)K activity in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9(7):936–943
111. Schomber T et al (2007) Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 67(22):10840–10848
112. Fischer C et al (2007) Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3):463–475
113. Bais C et al (2010) PI(3)K blockade does not inhibit angiogenesis during primary tumor growth. Cell 141(1):166–177
114. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116–129
181. Heo K et al (2012) Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol 48(6):500–506

182. Hall C et al (2017) Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Lett 386:179–188

183. Macaluso NJ et al (2011) Discovery of a competitive apelin receptor (APJ) antagonist. Chem Med Chem 6(6):1017–1023

184. Lv D et al (2016) PAK1-cofilin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13. Clin Exp Pharmacol Physiol 43(5):569–579

185. Berta J et al (2014) Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget 5(12):4426–4437

186. Sorli SC et al (2007) Apelin is a potent activator of tumour neangiogenesis. Oncogene 26(55):7692–7699

187. Sorli SC et al (2006) Therapeutic potential of interfering with apelin signalling. Drug Discov Today 11(23–24):1100–1106

188. Uribesalgo I et al (2019) Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. EMBO Mol Med 11(8):e9266

189. Mastrella G et al (2019) Targeting APLN/APLINR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma. Cancer Res 79(9):2298–2313

190. Harford-Wright E et al (2017) Pharmacological targeting of apelin impairs glioblastoma growth. Brain 140(11):2939–2954

191. Le Y et al (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1(2):95–104

192. Heidemann J et al (2003) Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR192. J Biol Chem 278(10):8508–8515

193. Keane MP et al (2004) Depletion of CXCR193 inhibits tumor angiogenesis in a murine model of lung cancer. J Immunol 172(5):2853–2860

194. Kitadai Y et al (2000) Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res 6(7):2735–2740

195. Iijichi H et al (2011) Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ducal adenocarcinoma. J Clin Invest 121(10):4106–4117

196. Yang G et al (2010) CXCR196 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 16(15):3875–3886

197. Smith ML, Olson TS, Ley K (2004) CXCR197- and E-selectin-induced neutrophil arrest during inflammation in vivo. J Exp Med 200(7):935–939

198. Smith DR et al (1994) Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 179(5):1409–1415

199. Ha H, Debnath B, Neamati N (2017) Role of the CXCL8-CXCR199/2 axis in cancer and inflammatory diseases. Theranostics 7(6):1543–1588

200. Martin D, Galisteo R, Gutkind JS (2009) CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFκappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284(10):6038–6042

201. Scapini P et al (2004) CXCL1/macrophase inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 172(8):5034–5040

202. Zhao X et al (2009) ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels. J Immunol 182(5):3213–3222

203. Li A et al (2005) Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8(1):63–71

204. Kobayashi Y (2008) The role of chemokines in neutrophil biology. Front Biosci 13:2400–2407

205. Sozzani S et al (2015) Chemokines as effector and target molecules in vascular biology. Cardiovasc Res 107(3):364–372

206. Xu J et al (2017) Vascular CXCR206 expression promotes vessel sprouting and sensitivity to sorafenib treatment in hepatocellular carcinoma. Clin Cancer Res 23(15):4482–4492

207. Ceradini DJ et al (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10(8):858–864

208. Wolf MJ et al (2012) Endothelial CXCR208 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 22(1):91–105

209. Chen X et al (2016) CCL2/CXCR209 regulates the tumor microenvironment in HER-2/neu-driven mammary carcinomas in mice. PLoS One 11(11):e0165595

210. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14(2):163–176

211. Gupta MK, Qin RY (2003) Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 9(6):1144–1155

212. Sainson RC et al (2008) TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 111(10):4997–5007

213. Muramatsu T (2002) Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 132(3):359–371

214. Lu KV et al (2005) Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 280(29):26953–26964

215. Chen H et al (2009) Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vascularogenesis. Blood 113(9):1992–2002

216. Zhang L et al (2015) Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Sci Signal 8(406):ra125

217. Acevedo L et al (2004) A new role for Nogo as a regulator of angiogenesis. Blood 113(9):1992–2002

218. Yu J et al (2009) Reticulon 4B (Nogo-B) is necessary for macrophage infiltration and tissue repair. Proc Natl Acad Sci USA 106(41):17511–17516

219. Zhu B et al (2017) Knockout of the Nogo-B gene attenuates tumor growth and metastasis in hepatocellular carcinoma. Neuroplasia 19(7):583–593

220. Cai H et al (2018) Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma. Mol Oncol 12(12):2042–2054

221. Cai H et al (2018) Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma. Mol Oncol 12(12):2042–2054

222. Lv X et al (2017) The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes Dis 4(1):19–24

223. Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26(2):281–290

224. Miller F et al (2005) Inactivation of VHL by tumorigenic transformation. Mol Cell 19(2):163–176

225. Sozzani S et al (2015) Chemokines as effector and target molecules in vascular biology. Cardiovasc Res 107(3):364–372

226. Cytogenet Cell Genet 88(1–2):101–102

227. Acovedo L et al (2004) A new role for Nogo as a regulator of vascular remodeling. Nat Med 10(4):382–388

228. Yu J et al (2009) Reticulon 4B (Nogo-B) is necessary for macrophage infiltration and tissue repair. Proc Natl Acad Sci USA 106(41):17511–17516

229. Zou B et al (2017) Knockout of the Nogo-B gene attenuates tumor growth and metastasis in hepatocellular carcinoma. Neuroplasia 19(7):583–593
246. Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16(7):431–446

247. Kumar V et al (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37(3):208–220

248. Jacob A, Prekeris R (2015) The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol 3:4

249. Horikawa N et al (2017) Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res 23(2):587–599

250. Karakhanova S et al (2015) Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncoimmunology 4(4):e998519

251. Chun E et al (2015) CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep 12(2):244–257

252. Obermaier N et al (2011) PGE(2)-induced CXCL12 production and CXCR252 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71(24):7463–7470

253. Shojaei F et al (2007) BV8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450(7171):825–831

254. Piao Y et al (2012) Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 14(11):1379–1392

255. Hao Z, Sadek I (2016) Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther 9:5495–5505

256. van Hoorren L et al (2016) Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget 7(31):50277–50289

257. Teczchio C et al (2013) On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol 23(3):159–170

258. Mueller MD et al (2000) Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil Steril 74(1):107–112

259. Heryanto B, Girling JE, Rogers PA (2004) Intravascular neutrophils partially mediate the endometrial endothelial cell proliferative response to oestrogen in ovariectomised mice. Reproduction 127(5):613–620

260. Shaw JP et al (2003) Polymorphonuclear neutrophils promote tumor angiogenesis: causes, consequences, challenges and opportunities. Front Cell Dev Biol 3:4

261. Benelli R et al (2002) Neutrophils as a key cellular target for the immune system in the tumor microenvironment. J Immunol 168(5):244–255

262. Shin Z et al (2012) Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol 29(4):2718–2726

263. Welford AP et al (2011) TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 121(5):1969–1973

264. Bronte V et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150

265. Parker KH, Beatty DW, Ostrand-Rosenberg S (2015) Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 128:95–139

266. Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16(7):431–446

267. Kumar V et al (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37(3):208–220

268. Jacob A, Prekeris R (2015) The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol 3:4

269. Horikawa N et al (2017) Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res 23(2):587–599

270. Karakhanova S et al (2015) Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncoimmunology 4(4):e998519

271. Chun E et al (2015) CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep 12(2):244–257

272. Obermaier N et al (2011) PGE(2)-induced CXCL12 production and CXCR252 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71(24):7463–7470

273. Shojaei F et al (2007) BV8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450(7171):825–831

274. Piao Y et al (2012) Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 14(11):1379–1392

275. Hao Z, Sadek I (2016) Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther 9:5495–5505

276. van Hoorren L et al (2016) Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget 7(31):50277–50289

277. Teczchio C et al (2013) On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol 23(3):159–170

278. Mueller MD et al (2000) Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil Steril 74(1):107–112

279. Heryanto B, Girling JE, Rogers PA (2004) Intravascular neutrophils partially mediate the endometrial endothelial cell proliferative response to oestrogen in ovariectomised mice. Reproduction 127(5):613–620

280. Shaw JP et al (2003) Polymorphonuclear neutrophils promote tumor angiogenesis: causes, consequences, challenges and opportunities. Front Cell Dev Biol 3:4

281. Benelli R et al (2002) Neutrophils as a key cellular target for the immune system in the tumor microenvironment. J Immunol 168(5):244–255

282. Shin Z et al (2012) Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol 29(4):2718–2726

283. Welford AP et al (2011) TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 121(5):1969–1973

284. Bronte V et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150

285. Parker KH, Beatty DW, Ostrand-Rosenberg S (2015) Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 128:95–139

286. Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16(7):431–446
311. Sorensen AG et al (2009) A “vascular normalization index” as a potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69(13):5296–5300

312. Batchelor TT et al (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059–19064

313. Sorensen AG et al (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72(2):402–407

314. Shrimali RK et al (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70(15):6171–6180

315. Yang J, Yan J, Liu B (2018) Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 9:978

316. Xin H et al (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69(6):2506–2513

317. Adotevi O et al (2010) A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 33(9):991–998

318. Martino EC et al (2016) Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov 2:16025

319. Olsson AK (2014) Therapeutic vaccination targeting the tumour vasculature. Biochem Soc Trans 42(6):1653–1657

320. Huijbers EJ et al (2010) Vaccination against the extra domain-B of fibronectin as a novel tumor vaccine. J Exp Med 220(2):212–226

321. Fuzesi L et al (2014) Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer. Oncotarget 5(23):12418–12427

322. Chaudhary A et al (2012) TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 21(2):212–226

323. Sotz C et al (2018) Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest 128(7):2927–2943

324. Byrd TT et al (2018) TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res 78(2):489–500

325. Hamzah J et al (2008) Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest 118(5):1691–1699

326. Johansson A et al (2012) Tumor-targeted TNFαlpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 109(20):7841–7846

327. Khan KA, Kerbel RS (2018) Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 15(5):310–324

328. Georgiannakou M, van Hoorik L, Dimberg A (2018) Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol 9:3081

329. Hayasaka H et al (2010) Neogenesis and development of the high endothelial venules that mediate lymphocyte trafficking. Cancer Sci 101(11):2302–2308

330. Hindley JP et al (2012) T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res 72(21):5473–5482

331. Colbeck EJ et al (2017) Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunol Res 5(11):1005–1015

332. Allen E et al (2017) Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 9(385):eaak9679

333. He B et al (2018) Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. J Pathol 245(2):209–221

334. Patel MM, Patel BM (2017) Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs 31(2):109–133

335. Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550

336. Tewari KS et al (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390(10103):1654–1663

337. Perren TJ et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484–2496

338. Escudier B et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111

339. Wick W et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963

340. Fuchs CS et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39

341. Tabernero J et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508

342. Zhu AX et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alphafetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282–296

343. Garon EB et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673

344. Bonner JA et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578

345. Heinemann V et al (2014) FOLFIRI plus cetuximab versus FOL-FIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065–1075

346. Price TJ et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15(6):569–579

347. Thatcher N et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16(7):763–774

348. Gianni L et al (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15(6):640–647

349. Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

Hurvitz SA et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19(1):115–126

Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

Brose MS et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319–328

Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338

Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513

Motzer RJ et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590

Dematteo RP et al (2009) Adjutant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104

Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417

Fielding AK et al (2014) UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123(6):843–850

Motzer RJ et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731

van der Graaf WT et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879–1886

Kim ES et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–1818

Lee SM et al (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 13(11):1161–1170

Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966

Wells SA Jr et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomised, double-blind phase III trial. J Clin Oncol 30(2):134–141

Li J et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONFUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619–629

Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302

Bruix J et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56–66

Martin M et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700

Baselga J et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640

Sequist LV et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334

Rini BI et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939

Abou-Alfa GK et al (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379(1):54–63

Elisei R et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639–3646

Powles T et al (2018) Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 119(6):663–669

Kudo M et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1162–1173

Sclumberger M et al (2015) Lenvatinib versus placebo in radioidine-refractory thyroid cancer. N Engl J Med 372(7):621–630

Tabernero J et al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50(2):320–331

Rajkumar SV et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20(21):4319–4323

Rajkumar SV et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29–37

Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456

Baselga J et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529

Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523

Pavel ME et al (2017) Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(10):1411–1422

Franz DN et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125–132

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.